Incorporating patient preference into the management of infertility in women with polycystic ovary syndrome

被引:1
作者
Okoroafor, Ugochi C. [1 ]
Jungheim, Emily S. [1 ]
机构
[1] Washington Univ, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, St Louis, MO 63108 USA
来源
PATIENT PREFERENCE AND ADHERENCE | 2012年 / 6卷
关键词
polycystic ovary syndrome; anovulation; clomiphene citrate; letrozole; metformin; obesity; IN-VITRO FERTILIZATION; CLOMIPHENE CITRATE; OVULATION INDUCTION; METFORMIN; PREGNANCY; RISK; LETROZOLE; SUCCESS; PLACEBO; OBESITY;
D O I
10.2147/PPA.S25286
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polycystic ovary syndrome (PCOS) is a heterogeneous condition characterized by anovulation, hyperandrogenism, and polycystic ovaries. Because of the heterogeneous nature of PCOS, women affected by the condition often require a customized approach for ovulation induction when trying to conceive. Treating symptoms of PCOS in overweight and obese women should always incorporate lifestyle changes with the goal of weight-loss, as many women with PCOS will ovulate after losing 5%-10% of their body weight. On the other hand, other factors must be considered including the woman's age, age-related decline in fertility, and previous treatments she may have already tried. Fortunately, multiple options for ovulation induction exist for women with PCOS. This paper reviews specific ovulation induction options available for women with PCOS, the benefits and efficacy of these options, and the related side effects and risks women can anticipate with the various options that may affect treatment adherence. The paper also reviews the recommended evidence-based strategies for treating PCOS-related infertility that allow for incorporation of the patient's preference. Finally, it briefly reviews emerging data and ongoing studies regarding newer agents that have shown great promise as first-line agents for the treatment of infertility in women with PCOS.
引用
收藏
页码:407 / 415
页数:9
相关论文
共 44 条
  • [1] Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc10-S062, 10.2337/dc14-S081, 10.2337/dc11-S011, 10.2337/dc13-S011, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc12-s011]
  • [2] [Anonymous], 2009, Obstet Gynecol, V114, P936, DOI 10.1097/AOG.0b013e3181bd12cb
  • [3] [Anonymous], ANN ART SUCC RAT REP
  • [4] [Anonymous], 1992, POLYCYSTIC OVARY SYN
  • [5] [Anonymous], K RYAN ETH S P 67 AN
  • [6] Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation
    Atay, V
    Cam, C
    Muhcu, M
    Cam, M
    Karateke, A
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2006, 34 (01) : 73 - 76
  • [7] The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report
    Azziz, Ricardo
    Carmina, Enrico
    Dewailly, Didier
    Diamanti-Kandarakis, Evanthia
    Escobar-Morreale, Hector F.
    Futterweit, Walter
    Janssen, Onno E.
    Legro, Richard S.
    Norman, Robert J.
    Taylor, Ann E.
    Witchel, Selina F.
    [J]. FERTILITY AND STERILITY, 2009, 91 (02) : 456 - 488
  • [8] Balen Adam H, 2007, Hum Fertil (Camb), V10, P195, DOI 10.1080/14647270701731290
  • [9] Treatment preferences and trade-offs for ovulation induction in clomiphene citrate-resistant patients with polycystic ovary syndrome
    Bayram, N
    van Wely, M
    van der Veen, F
    Bossuyt, PMM
    [J]. FERTILITY AND STERILITY, 2005, 84 (02) : 420 - 425
  • [10] Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial
    Bayram, N
    van Wely, M
    Kaaijk, EM
    Bossuyt, PMM
    van der Veen, F
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7433): : 192 - 195